Health-related quality of life of men with primary osteoporosis and its changes after bisphosphonates treatment

• Published in: BMC musculoskeletal disorders Vol. 24; no. 1; p. 309
• Main Authors: Zhao, Di-Chen, Lin, Xiao-Yun, Hu, Jing, Zhou, Bing-Na, Zhang, Qian, Wang, Ou, Jiang, Yan, Xia, Wei-Bo, Xing, Xiao-Ping, Li, Mei
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 19.04.2023; BioMed Central; BMC
• Subjects: Alendronic acid; Bisphosphonates; Bone Density; Bone diseases; Bone Diseases, Metabolic - drug therapy; Bone mineral density; Bones; Care and treatment; Collagen (type I); Density; Diagnosis; Diphosphonates - therapeutic use; Drugs; Endocrinology; Female; Fractures; Fractures, Bone; Health aspects; HRQoL; Humans; Male; Males; Men; Metabolism; Mortality; Musculoskeletal diseases; Osteopenia; Osteoporosis; Osteoporosis - drug therapy; Patients; Procollagen; Quality of Life; Questionnaires; Serum levels; SF-36; Spine; Womens health; Zoledronic acid; China; Osteoporosis; HRQoL; Males; Bisphosphonates; SF-36

Osteoporosis leads to more serious consequences in men than in women, but less is known about its impacts on health-related quality of life (HRQoL) of men, and whether the anti-osteoporosis treatment can improve HRQoL of men with osteopenia/osteoprosis. We enrolled men with primary osteoporosis and...